Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PHIBRO ANIMAL HEALTH CORPPAHC · Entity 4671 | Director · Executive Chairman · 10% owner | August 06, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PHIBRO ANIMAL HEALTH CORP
Report date August 06, 2026 · Filed August 10, 2026
Jointly reported with BFI Co., LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 26,640 |
Reported balance
After 2026-08-06 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-08-06 · Grant · Acquired 12,103 · Balance 26,640 F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date. F3: The reported securities are directly held by Jack Bendheim. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee | 56,152 |
Reported balance
Holding disclosure · report date 2026-08-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 56,152 F4: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.
F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date.
F3: The reported securities are directly held by Jack Bendheim.
F4: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2026 Filed Mar 16, 2026 20:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-028472 · tm268840-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 101,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 00:09 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 711 | $54.28 | $38,594.93 |
DisclosureSEC source: 0001104659-26-020787 · tm267373-1_4seq1.xml · nonDerivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 1,480 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.27 to $54.355. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 00:09 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 6,329 | $53.67 | $339,671.10 |
DisclosureSEC source: 0001104659-26-020787 · tm267373-1_4seq1.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 2,191 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.21 to $54.10. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 00:09 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 7,040 | $51.71 | $364,041.22 |
DisclosureSEC source: 0001104659-26-020787 · tm267373-1_4seq1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 8,520 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.275 to $52.27. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 00:09 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,151 | $51.88 | $59,713.76 |
DisclosureSEC source: 0001104659-26-020787 · tm267373-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 15,560 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.80 to $52.065. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 00:09 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 5,889 | $51.27 | $301,916.66 |
DisclosureSEC source: 0001104659-26-020787 · tm267373-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 16,711 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.755 to $51.75. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 7. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:30 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 397 | $51.96 | $20,629.87 |
DisclosureSEC source: 0001104659-26-018606 · tm266984-1_4seq1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 22,600 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.92 to $52.06. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:30 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 6,643 | $51.38 | $341,337.27 |
DisclosureSEC source: 0001104659-26-018606 · tm266984-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 22,997 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.90 to $51.89. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:30 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 7,040 | $50.26 | $353,807.87 |
DisclosureSEC source: 0001104659-26-018606 · tm266984-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 29,640 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.965 to $50.935. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 and 5. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 00:40 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 216 | $51.97 | $11,225.26 |
DisclosureSEC source: 0001104659-26-017198 · tm266654-1_4seq1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 36,680 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.90 to $52.05. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 00:40 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 6,824 | $51.38 | $350,599.38 |
DisclosureSEC source: 0001104659-26-017198 · tm266654-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 36,896 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.90 to $51.875. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 00:40 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 7,040 | $51.96 | $365,821.63 |
DisclosureSEC source: 0001104659-26-017198 · tm266654-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 43,720 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.61 to $52.345. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 and 5. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 11, 2026 Filed Feb 11, 2026 23:27 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 234 | $52.21 | $12,216.53 |
DisclosureSEC source: 0001104659-26-013602 · tm265965-1_4seq1.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 50,760 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.205 to $52.21. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 11, 2026 Filed Feb 11, 2026 23:27 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 13,950 | $51.61 | $719,969.27 |
DisclosureSEC source: 0001104659-26-013602 · tm265965-1_4seq1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 50,994 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.11 to $52.04. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 23:27 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 7,020 | $52.17 | $366,254.46 |
DisclosureSEC source: 0001104659-26-013602 · tm265965-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 64,944 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.10 to $52.30. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 23:27 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 50,994 | $51.76 | $2,639,270.96 |
DisclosureSEC source: 0001104659-26-013602 · tm265965-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 71,964 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.10 to $52.09. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4, 5 and 6. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 185,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · derivative · entry 9 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 19,696,034 Underlying: Class A Common Stock · 185,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 19,138 | $49.57 | $948,705.11 |
DisclosureSEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · nonDerivative · entry 7 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 122,958 F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025. F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.18 to $50.01. F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 46,275 | $48.65 | $2,251,417.58 |
DisclosureSEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · nonDerivative · entry 6 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 142,096 F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025. F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.175 to $49.17. F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 38,209 | $47.91 | $1,830,421.25 |
DisclosureSEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · nonDerivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 188,371 F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.17 to $48.17. F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 3,171 | $46.68 | $148,027.35 |
DisclosureSEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 226,580 F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.10 to $47.08. F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 3,640 | $45.42 | $165,344.09 |
DisclosureSEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 229,751 F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.04 to $46.02. F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 409 | $44.47 | $18,187.74 |
DisclosureSEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 233,391 F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.035 to $44.73. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 5 through 9. F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 185,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 233,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 00:22 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011113 · tm265335-1_4seq1.xml · derivative · entry 6 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 19,881,034 Underlying: Class A Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F5 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 00:22 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 3,520 | $41.15 | $144,863.49 |
DisclosureSEC source: 0001104659-26-011113 · tm265335-1_4seq1.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 48,800 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.535 to $41.52. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 00:22 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-011113 · tm265335-1_4seq1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 52,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:22 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,971 | $41.97 | $124,683.07 |
DisclosureSEC source: 0001104659-26-011113 · tm265335-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 22,320 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.70 to $42.62. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:22 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 6,689 | $41.25 | $275,926.60 |
DisclosureSEC source: 0001104659-26-011113 · tm265335-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 25,291 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.69 to $41.68. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 and 6. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 6,693 | $40.09 | $268,349.81 |
DisclosureSEC source: 0001104659-26-009210 · tm264637-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 31,980 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.365. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 6,772 | $40.12 | $271,687.22 |
DisclosureSEC source: 0001104659-26-009210 · tm264637-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 38,673 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.475. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 4. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-006986 · tm264120-1_4seq1.xml · derivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 19,911,034 Underlying: Class A Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F4 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-006986 · tm264120-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 45,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,235 | $40.55 | $50,083.94 |
DisclosureSEC source: 0001104659-26-006986 · tm264120-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 15,445 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.175 to $41.01. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 00:41 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,283 | $42.68 | $54,755.10 |
DisclosureSEC source: 0001104659-26-005914 · tm263655-2_4seq1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 16,680 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.62 to $42.77. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 00:41 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 11,875 | $41.91 | $497,664.63 |
DisclosureSEC source: 0001104659-26-005914 · tm263655-2_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 17.963 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.58 to $42.53. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 00:41 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 14,687 | $41.68 | $612,127.72 |
DisclosureSEC source: 0001104659-26-005914 · tm263655-2_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 29,838 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.11 to $42.02. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 and 5. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 15, 2026 Filed Jan 15, 2026 23:24 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,932 | $40.02 | $117,348.32 |
DisclosureSEC source: 0001104659-26-004189 · tm263276-1_4seq1.xml · nonDerivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 44,525 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.07. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 14, 2026 Filed Jan 15, 2026 23:24 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-004189 · tm263276-1_4seq1.xml · derivative · entry 7 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 19,941,034 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F4 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 14, 2026 Filed Jan 15, 2026 23:24 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 393 | $41.14 | $16,167.04 |
DisclosureSEC source: 0001104659-26-004189 · tm263276-1_4seq1.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 47,457 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.125 to $41.15. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 14, 2026 Filed Jan 15, 2026 23:24 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 3,258 | $40.46 | $131,816.07 |
DisclosureSEC source: 0001104659-26-004189 · tm263276-1_4seq1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 47,850 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.025 to $40.985. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 14, 2026 Filed Jan 15, 2026 23:24 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-004189 · tm263276-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 51,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 23:24 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 7,551 | $40.32 | $304,421.59 |
DisclosureSEC source: 0001104659-26-004189 · tm263276-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 31,108 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.09 to $40.51. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 5, 6 and 7. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 23:53 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 213 | $40.16 | $8,554.08 |
DisclosureSEC source: 0001104659-26-003467 · tm262975-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 38,659 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F2 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 23:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 328 | $40.09 | $13,148.77 |
DisclosureSEC source: 0001104659-26-002221 · tm262516-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 38,872 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.035 to $40.26. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 21:51 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,995 | $41.22 | $123,444.02 |
DisclosureSEC source: 0001104659-25-121213 · tm2533388-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 39,200 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.095 to $41.38. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 21:51 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,757 | $40.61 | $111,960.67 |
DisclosureSEC source: 0001104659-25-121213 · tm2533388-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 42,195 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.035 to $41.025. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 4. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,288 | $40.19 | $51,763.30 |
DisclosureSEC source: 0001104659-25-119982 · tm2533142-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 44,952 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.01 to $40.34. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 3,520 | $40.06 | $141,017.54 |
DisclosureSEC source: 0001104659-25-119982 · tm2533142-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 46,240 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.195. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 4. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 04, 2025 Filed Dec 4, 2025 23:34 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 368 | $41.75 | $15,364.63 |
DisclosureSEC source: 0001104659-25-118545 · tm2532723-1_4seq1.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 49,760 F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.73 to $41.775. F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.